Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2021 | Real-world findings of MRD by MFC in AML

Bruno Paiva • 24 Feb 2021
EMN 2021
Acute Myeloid Leukemia Leukemia

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, shares an outline of the PETHEMA real-world study investigating the impact of measurable residual disease (MRD) by multiparameter flow cytometry (MFC) in patients with acute myeloid leukemia (AML). The study analyzed data from 1076 patients with AML in first remission after induction chemotherapy. Dr Paiva reports that decentralized MRD assessment after the first cycle of intensive chemotherapy shows limited clinical significance versus other prognostic factors. This interview took place during the 2021 European Myeloma Network (EMN) congress.

More from Bruno Paiva

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
Bruno Paiva et al. • 25 Mar 2024
2:08
Minimally invasive assessment of MRD in multiple myeloma
Bruno Paiva • 9 Dec 2023
2:34
Mutant hematopoietic progenitor cells in MM associated with secondary primary malignancies
Bruno Paiva • 9 Dec 2023
1:52
Clinical significance of MRD status in patients with MM treated with CAR-T and T-cell engagers
Bruno Paiva • 9 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals